Get started
Author

Kornelia Kittel

Observed names: K Kittel, K. Kittel, Kittel, K.
Institutions: Universität Ulm, Universitätsklinikum Erlangen, Universitätsmedizin Göttingen, University Hospital Magdeburg, Comprehensive Cancer Center Erlangen, University Hospital Ulm, Martin Luther University Halle-Wittenberg, Charité - Universitätsmedizin Berlin
Observed institutions: University of Cologne, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universität Ulm, Kantonsspital St. Gallen, University Medical Center Freiburg, Universitätsklinikum Erlangen, University Medical Center Hamburg-Eppendorf, Sankt Gertrauden Krankenhaus, University Hospital Schleswig-Holstein, Luisenkrankenhaus, Universitätsmedizin Göttingen, Universitäts Frauenklinik, German Breast Group, University Hospital Frankfurt, University Hospital Magdeburg, Sana Klinikum Offenbach, St.-Johannes-Hospital Dortmund, Rotkreuzklinikum München, Comprehensive Cancer Center Erlangen, Evangelische Kliniken Gelsenkirchen, University Hospital Ulm, Helios Hospital Berlin-Buch, University of Rostock, Martin Luther University Halle-Wittenberg, Charité - Universitätsmedizin Berlin, University of Tübingen, Ludwig-Maximilians-Universität München, Otto-von-Guericke-Universität Magdeburg
OpenAlex ID: A5022758199
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
2012 · Gunter von Minckwitz, Holger Eidtmann, et al. · New England Journal of Medicine · 530
Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
2013 · B. Gerber, S. Loibl, et al. · Annals of Oncology · 150
PDF
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
2014 · G. von Minckwitz, G. von Minckwitz, et al. · Annals of Oncology · 137
Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes
2014 · Silvia Darb-Esfahani, Gunter von Minckwitz, et al. · BMC Cancer · 87
PDF
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44)
2013 · Jens Huober, Peter A. Fasching, et al. · European Journal of Cancer · 79
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III G epar Q uinto study
2015 · Alexander Hein, Diether Lambrechts, et al. · International Journal of Cancer · 33
PDF
Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44)
2014 · Bernd Gerber, Gunter von Minckwitz, et al. · Annals of Surgical Oncology · 28
Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44).
2011 · B. Gerber, H. Eidtmann, et al. · Journal of Clinical Oncology · 23
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial
2019 · Melanie Janning, Volkmar Müller, et al. · International Journal of Cancer · 18
PDF
Abstract S4-6: Neoadjuvant Chemotherapy with or without Bevacizumab: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44)
2010 · G von Minckwitz, H Eidtmann, et al. · Cancer Research · 16
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
2008 · Peter Schmid, J. Krocker, et al. · Cancer Chemotherapy and Pharmacology · 14
Abstract PD04-06: Changes in Circulating Tumor and Endothelial Cells in Peripheral Blood of Patients Treated in the Neoadjuvant Chemotherapy Plus Targeted Treatment Breast Cancer Study “GeparQuinto”
2010 · S Riethdorf, V Mueller, et al. · Cancer Research · 13
S3-6: Neoadjuvant Chemotherapy of Paclitaxel with or without Rad001: Results of the Non-Responder Part of the GEPARQUINTO Study (GBG 44).
2011 · J Huober, C Hanusch, et al. · Cancer Research · 7
Non-pegylated liposomal doxorubicin and docetaxel as first-line treatment in metastatic breast cancer
2005 · V. Heilmann, H. Eggemann, et al. · Journal of Clinical Oncology · 4
P1-14-05: Surgical Complications from the GeparQuinto Trial of Patients Receiving Preoperative Bevacizumab.
2011 · H Eidtmann, K Kittel, et al. · Cancer Research · 3
1801 Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44)
2015 · M. Untch, G. Von Minckwitz, et al. · European Journal of Cancer · 2
Abstract P1-13-01: Final results of the ASG1-3 study, a randomized phase III study comparing a standard dose chemotherapy with epirubicin/cyclophosphamide and paclitaxel with a dose dense regimen with epirubicin and paclitaxel
2019 · PA Fasching, H Eggemann, et al. · Cancer Research · 1
Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b.
2017 · Mark Wroblewski, Janna-Lisa Velthaus, et al. · Journal of Clinical Oncology · 1
1570 The compatibility of biosimilar filgrastim under cytotoxic chemotherapy in the treatment of malignant diseases: VENICE study
2015 · B. Otremba, C. Salat, et al. · European Journal of Cancer · 1
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial
2016 · Melanie Janning, E. Müller, et al.
Abstract P3-11-01: Neoadjuvant chemotherapy with or without bevacizumab or everolimus: Survival analysis of The HER2-negative cohort of the GEPARQUINTO study (GBG 44)
2015 · Bernd Gerber, Sibylle Loibl, et al. · Cancer Research
Palonosetron-based antiemetic prophylaxis in breast cancer patients receiving AC chemotherapy – registry data from German gynaeco-oncology practices
2014 · H.-J Hindenburg, J Schilling, et al.
Effektive antiemetische Prophylaxe mit Palonosetron bei Mammakarzinompatientinnen mit adjuvanter anthrazyklinhaltiger Chemotherapie
2012 · J Schilling, H Hindenburg, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Efficacy of palonosetron-based antiemetic prophylaxis in breast cancer patients receiving anthracycline-containing adjuvant chemotherapy: A survey in 41 German gyneco-oncology practices.
2012 · Joerg Peter Schilling, Peter Klare, et al. · Journal of Clinical Oncology
Detektion zirkulierender Tumor- und Endothelzellen unter neoadjuvanter Chemo- und zielgerichteter Therapie – ein translationales Forschungsprojekt der „GeparQuinto„-Studie
2011 · S Riethdorf, V Müller, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Works count: 27
Citation count: 1,284
H-index: 13
I10-index: 13
Year
Topic
Type